glp-1 and gallbladder GLP1-RAs diseases – is there a connection? – GP Voice GLP-1 & Gallbladder Disease: What

Description

Fatigue is actually listed as a common adverse reaction in the Summary of Product Characteristics (SmPC) for some GLP-1 receptor agonists, particularly those used at higher doses for weight management such as semaglutide 2.4mg (Wegovy) and liraglutide 3mg (Saxenda)

This dual mechanism regulates appetite, slows digestion, stabilizes blood sugar, and improves metabolic function

In high-fat diet fed mice, treatment with the triagonist dose-dependently improved steatohepatitis and reduced levels of ALT, underpinning the potential for this compound to treat liver disease ( 3 ) agonist has shown to reverse metabolic syndrome related abnormalities ( 3 lowered ALT levels and improved macroscopic and histological features of NASH, including reversal of fibrosis ( Conclusion and future perspectives New knowledge about the pathophysiology of NAFLD has been accumulating over the last decade, displaying the complexity of the mechanisms involved in the development of this condition

A 2023 study Trusted Source American Journal of Clinical Nutrition Go to source suggests there is high burden of obesity and other metabolic disorders, including type 2 diabetes, in inflammatory bowel disease (IBD) patients